A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Amgen (AMGN – Research Report) today. The company’s shares closed ...

With a smile is how Walker County couple, Andrea Phillips and her husband James Phillips like to go through life even through ...

New Ohio law restricts transgender students’ access to school restrooms, 'bathroom bill' sparks outcry Ohio Governor Mike DeWine recently signed the "Protect All Students Act," effectively ...

November 28, 2024 • In an episode we first posted in January, we go to the West African country of Ghana. The Ghanaian government began encouraging people of African descent from around the ...